Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor With Alterations of the FGF-R”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Testing effectiveness (Phase 2)Looking for participantsNCT06511648
What this trial is testing

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Who this might be right for
Muscle-invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group 90
Testing effectiveness (Phase 2)UnknownNCT05775874
What this trial is testing

Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Who this might be right for
Urothelial Carcinoma
Abbisko Therapeutics Co, Ltd 80
Testing effectiveness (Phase 2)Study completedNCT02924376
What this trial is testing

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Who this might be right for
Cholangiocarcinoma
Incyte Corporation 147
Early research (Phase 1)Study completedNCT01697605
What this trial is testing

A Phase I Study of Oral BGJ398 in Asian Patients

Who this might be right for
Tumor With Alterations of the FGF-R
Novartis Pharmaceuticals 9
Early research (Phase 1)Ended earlyNCT01948297
What this trial is testing

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Who this might be right for
Solid Tumours
Debiopharm International SA 77
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02872714
What this trial is testing

Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Who this might be right for
UC (Urothelial Cancer)
Incyte Corporation 263
Testing effectiveness (Phase 2)Active Not RecruitingNCT04595747
What this trial is testing

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Who this might be right for
Locally Advanced Gastrointestinal Stromal TumorLocally Advanced SarcomaMetastatic Gastrointestinal Stromal Tumor+5 more
National Cancer Institute (NCI) 48